Docket No.: 128497

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Patrice MARCHE et al.

Application No.: 10/586,742

Filed: July 21, 2006

For: COMPOSITION FOR TREATING PATHOLOGY ASSOCIATED WITH MSRV/HERV-W

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.
- One or more reference cited herein was cited in the International Search Report.
 An English language version of the International Search Report is attached for the Examiner's information. See References 1–6, 11, 12, 17, 88, and 89.

Respectfully submitted.

James/A. Oliff Registration No. 27.075

registration ivo. 27,070

Jeffrey R. Bousquet Registration No. 57,771

JAO:JRB/kxs

Date: January 4, 2007

OLIFF & BERRIDGE, PLC P.O. Box 19928 Alexandria, Virginia 22320 Telephone: (703) 836-6400 AUTHORIZATION
Please grant any extension
necessary for entry;
Charge any fee due to our
Deposit Account No. 15-0461

DEPOSIT ACCOUNT USE

Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 128497			APPLICATION NO. 10/586,742	
INFORMATION DISCLOSURE STATEMENT								
(Use several sheets if necessary)			APPLICANT(S) Patrice MARCHE et al.					
					FILING DATE July 21, 2006 GROUP		, ••	
		Ū.	S. PATEN	T DOCUM	MENTS			
Examiner Initials	Cite No.	Document Number	Da	ite	Name			
		FORE	EIGN PAT	ENT DOC	UMENTS			
Examiner Initials	Cite No.	Document Number	Da	ite	Country	With English Abstract	With English Translation	
	1	WO 01/31021 A1	5/03/	2001	WIPO	х		
	2	WO 01/031021 A1 (Corrected)	5/03/	2001	WIPO	х		
	3	WO 03/035110 A1	5/01/	2003	WIPO	х		
	4	WO 01/16171	3/08/	2001	WIPO	х		
	5	WO 95/21256	8/10/	1995	WIPO	х		
	6	WO 99/67395	12/29	/1999	WIPO	х		
			OTHER D	OCUME	VTS			
Examiner Initials	Cite No.	(Including Aut	hor, Title, l	Date, Perti	nent Pages, etc.)			
	7	Conrad, Bernard et al. "A Human Endo Cell, Vol. 90, pp. 303-313, July 25, 19	ogenous Re 97.	etroviral S	uperantigen as Candidate Autoimmune Ge	ne in Type 1 D	iabetes,"	
	8	Perron, H. et al. "Molecular identificati Proc. National Academy of Science US			rus repeatedly isolated from patients with 3-7588, July 1997.	multiple scleros	is,"	
	9	Deb-Rinker, Paromita et al. "Molecula Pairs Discordant for Schizophrenia," G			a MSRV-like Sequence Identified by RD/ 1. 133-144, 1999.	from Monozy	gotic Twin	
	10	Perron, H. et al. "Isolation of a Retrovirus from Patients with Multiple Sclerosis," The Lancet, Vol. 337, pp. 862 -863, April 6, 1991.			, April 6,			
	11	Blond, Jean-Luc et al. "Molecular Characterization and Placental Expression of HERV-W, a New Human Endogenous Retrovirus Pamily," <u>Journal of Virology</u> , Vol. 73, No. 2, pp. 1175-1185, February 1999.						
18	12	Perron, Herve et al. "Particle-associate components of a 'chain-reaction' trigge Supplement 2, pp. S67-S75, 2000.	d retroviral red by infe	RNA and ctious age	tandem RGH/HERV-W copies on human nts in multiple sclerosis?," <u>Journal of Neu</u>	chromosome 7 roVirology, Vol	q: possible l. 16,	
	13	Dolei, A. et al. "Multiple sclerosis-asso 2002.	ciated retr	ovirus (M	SRV) in Sardinian MS patients," <u>Neurolog</u>	y. Volume 58,	рр. 471-473,	
	14	Garson, J. A. et al. "Detection of virion 351, p. 33, January 3, 1998.	-associated	I MSRV-I	RNA in serum of patients with multiple scl	erosis," The La	ncet, Volume	
	15	Olsson, Patrik et al. "Retroviral RNA Related to ERV9/MSRV in a Human Serum: A New Sequence Variant," Aids Research and Human Retroviruses, Volume 15, No. 6, pp. 591-593, 1999.						
	16	Sotgiu, S. et al. "Multiple sclerosis-associated retrovirus and MS prognosis; an observational study," Neurology. Volume 59, pp. 1071-1073, 2002.						
	17	Perron, H. et al. "Multiple Sclerosis Retrovirus Particles and Recombinant Envelope Trigger an Abnormal Immune Response in Vitro, by Inducing Polyclonal V ₈ 16 T-Lymphocyte Activation," Virology, Volume 287, pp. 321-332, 2001.						
	Hrouzi, R. et al. "Multiple sclerosis-associated retrovirous particles cause T-lymphocyte-dependent death with brain hemorrhage in humanized SCID mice model," Journal of NeuroVirology, Volume 9, pp. 79-93, 2003.				hemorrhage			

19	Lin, A. et al. "The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6," <u>Schizophrenia Research</u> , Vol. 32, pp. 9-15, 1998.
20	Stevens, Janice R. "Neuropathology of Schizophrenia," Arch. Gen. Psychiatry, Volume 39, pp. 1131-1139, October 1982.
21	Karlsson, Hakan et al. "Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia," PNAS, Volume 98, No. 8, pp. 4634-4639, April 10, 2001.
22	Perron, H. et al. "Microbial Agents Triggering Endogenous Retroviruses within Genetic Susceptibility Loci Resulting in Expression of Superantigen and Gliotoxic Molecules: a plausible Immunovirogenetic Cascade Causing Multiple Sclerosis," Mod. Asp. Immunobiol, Volume 1, No. 5, pp. 198-203, 2001.
23	Liu, Yuxin et al. "Dextromethorphan Protects Dopaminergic Neurons against Inflammation-Mediated Degeneration through Inhibition of Microglial Activation," <u>Journal of Pharmacology and Experimental Therapeutics</u> , Vol. 305, pp. 212-218, 2003.
24	Morimoto, Kiyoshi et al. "Acute Neuroinflammation Exacerbates Excitotoxicity in Rat Hippocampus in Vivo," Experimental Neurology, Vol. 177, pp. 95-104, 2002.
2.5	Stoll, G. "Inflammatory cytokines in the nervous system: multifunctional mediators in autoimmunity and cerebral ischemia," Rev_Neurol , Vol. 158, No. 10, pp. 887-891, 2002.
26	Guillemin, Gilles J. et al. "Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease," Redox Report. Vol. 7, No. 4, 2002.
27	Kim, Eun Joo et al. "Neuroprotective Effects of Prostaglandin E ₂ or cAMP Against Microglial and Neuronal Free Radical Mediated Toxicity Associated With Inflammation," <u>Journal of Neuroscience Research</u> , Vol. 70, pp. 97-107, 2002.
28	Kim, Won-Gon. "Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia," Journal of Neuroscience, Vol. 20, pp. 6309-6316, August 15, 2000.
29	Klein, Christine et al. "Association Studies of Parkinson's Disease and parkin Polymorphisms," Letters to the Editor: Annals of Neurology, Vol. 48, No. 1, pp. 126-127, July 2000.
30	Licinio, J. et al. "The Role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection," <u>Molecular Psychiatry</u> , Vol. 4, pp. 317-327, 1999.
25	Cotter, Robin et al. "Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity," <u>Journal of Luckocyte Biology</u> , Vol. 65, pp. 416-427, April 1999.
26	Heese, Klaus. "Inflammatory Signals Induce Neurotrophin Expression in Human Microglial Cells," <u>Journal of Neurochemistry</u> . Vol. 70, No. 2, pp. 699-707, 1998.
27	Sasser, L. B. et al. "Subchronic Toxicity Evaluation of Lewisite in Rats," <u>Journal of Toxicology and Environmental Health</u> , Vol. 47, pp. 321-334, 1996.
28	Chao, Chun C. "Interleukin-1 and Tumor Necrosis Factor-α Synergistically Mediate Neurotoxicity: Involvement of Nitric Oxide and of N-Methyl-p-aspartate Receptors," Brain, Behavior and Immunity, Vol. 9, pp. 355-365, 1995.
29	Chao, Chun C. et al. "Tumor Necrosis Factor-Alpha Potentiates Glutamate Neurotoxicity in Human Fetal Brain Cell Cultures," <u>Dev. Neurosci.</u> , Vol. 16, pp. 172-179, 1994.
30	Bal-Price, Anna et al. "Inflammatory Neurodegeneration Mediated by Nitric Oxide from Activated Glia-Inhibition Neuronal Respiration, Causing Glutamate Release and Excitotoxicity," <u>Journal of Neuroscience</u> , Vol. 21, No. 17, pp. 6480-6491, September 2001.
31	Obrenovitch, T. P. "Quinolinic Acid Accumulation During Neuroinflammation," <u>Annals New York Academy of Sciences</u> , Vol. 239, pp. 1-10, 2001.
32	Law, A. et al. "Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type," Brain Research Reviews, Vol. 35, pp. 73-96, 2001.
33	Werner, P. et al. "Glutamate excitotoxicity-a mechanism for axonal damage and oligodendrocyte death in Multiple Sclerosis?," <u>Journal Neural. Transm.</u> , Vol. 60, Supplement, pp. 375-385, 2000.
34	Pitt, David et al. "Glutamate excitotoxicity in a model of multiple sclerosis," Nature Medicine, Vol. 6, No. 1, pp. 67-70, January 2000.
35	Carlson, Noel G. et al. "Inflammatory Cytokines IL-1 _{g.} IL-1 _{g.} IL-6, and TFN- ₉ Impart Neuroprotection to an Excitotoxin Through Distict Pathways." <u>Journal of Immunology</u> . Vol. 163, pp. 3963-3968, 1999.
36	Wang, Yushan S. et al. "The Bacterial Endotoxin Lipopolysaccharide Causes Rapid Inappropriate Excitation in Rat Cortex," <u>Journal of Neurochemistry.</u> Vol. 72, No. 2, pp. 652-660, 1999.
37	Yolken, R. H. "Endogenous Retroviruses and Schizophrenia," Brain Research Reviews, Vol. 31, pp. 193-199, 2000.
38	Kleine, Tilmann O. et al. "Approach to discriminate subgroups in multiple sclerosis with cerebrospinal fluid (CSF) basic inflammation indices and TNF-α, IL-1 ₈ , IL-6, IL-8," <u>Brain Research Bulletin</u> . Vol. 61, pp. 327-346, 2003.
39	Aarli, Johan A. "Role of Cytokines in Neurological Disorders," Current Medicinal Chemistry, Vol. 10, pp. 1931-1937, 2003.

40	Vladic, Anton et al. "Cerebrospinal Fluid and Serum Protein Levels of Tumour Necrosis Factor-Alpha (TNF-a), Interleukin-6 (IL-6) and Soluble Interleukin-6 Receptor (sIL-6R gp80) in Multiple Sclerosis Patients," Cytokine , Vol. 20, No. 2, pp. 86-89, Oct. 21, 2002.
41	Miljkovic, Dj. et al. "Nitric oxide metabolites and interleukin-6 in Cerebrospinal fluid from multiple sclerosis patients," European Journal of Neurology, Vol. 9, pp. 413-418, 2002.
42	Clerici, Mario. "Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease," <u>Journal of Neuroimmunology</u> , Vol. 121, pp. 88-101, 2001.
43	Fedetz, Maria. "The -174/-597 promoter polymorphisms in the interleukin-6 gene are not associated with susceptibility to multiple sclerosis," <u>Journal of Neurological Sciences</u> , Vol. 190, pp. 69-72, 2001.
44	Stelmasiak, Zbigniew et al. "IL-6 and sIL-6R concentration in the cerebrospinal fluid and serum of MS patients," Med. Sc Monit., Vol. 7, No. 5, pp. 914-918, 2001.
45	Vandenbroeck, K. "High-resolution analysis of IL-6 minisatellite polymorphism in Sardinian multiple sclerosis: effect on course and onset of disease, "Genes and Immunology, Vol. 1, pp. 460-463, 2000.
46	Stelmasiak, Zbigniew. "Interleukin-6 concentration in serum and cerebrospinal fluid in multiple sclerosis patients," <u>Med Sci.</u> <u>Monit.</u> Vol. 6, No. 6, pp 1104-1108, 2000.
47	Schonrock, Lisa et al. "Interleukin-6 expression in human multiple sclerosis lesions," Neuroscience Letters, Vol. 294, pp. 45-48, 2000.
48	Cornford, Eain M. et al. "New systems for delivery of drugs to the brain in neurological disease," <u>Lancet Neurology</u> , Vol. 1, pp. 306-315, September 2002.
49	Schmidt, Jens et al. "Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis," <u>Brain</u> , Vol. 126, pp. 1895-1904, 2003.
50	Pardridge, William M. "Blood-Brain Barrier Drug Targeting Enables Neuroprotection in Brain Ischemia Following Delayed Intravenous Administration of Neurotrophins," <u>Adv. Exp. Med. Biol.</u> , pp. 397-430, 2002.
51	Watanabe, Satoru et al. "Chemotherapeutic Targeting of Etoposide to Regions of the Brain on the Basis of Polyamine Level," <u>Journal of Drug Targeting</u> , Vol. 10, No. 6, pp. 457-461, 2002.
52	Lahiri, Debomoy K. et al. "A Critical Analysis of New Molecular Targets and Strategies for Drug Developments in Alzheimer's Disease," Current Drugs Targets, Vol. 4, pp. 97-112, 2003.
53	Scherrmann, J. M. "Drug delivery to brain via the blood-brain barrier," Vascular Pharmacology, Vol. 38, pp. 349-354, 2002.
54	Wang, Jian-Xin et al. "Enhanced brain targeting by synthesis of 3', 5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles," European Journal of Pharmaceuticals and Biopharmaceuticals. Vol. 54, pp. 285-290, 2002.
55	Doan, Kelly M. Mahar et al. "Passive Permeability and P-Glycoprotein-Mediated Efflux Differentate Central Nervous System (CNS) and Non-CNS Marketed Drugs," Journal of Pharmacology and Experimental Therapeutics. Vol. 303, pp. 1029-1037, 2002.
56	Hosoya, Ken-ichi et al. "Recent advances in the brain-to-blood efflux transport across the blood-brain barrier," <u>International</u> <u>Journal of Pharmaceuticals</u> , Vol. 248, pp. 15-29, 2002.
57	Mora, Margarita. "Design and Characterization of Liposomes Containing Long-Chain-N AcylPE, for Brain Delivery: Penetration of Liposome Incorporating GM ₁ into the Rat Brain," <u>Pharmaceutical Research</u> , Vol. 19, No. 10, October 2002.
58	Perron, H. et al. "Herpes simplex virus ICPO and ICP4 immediate early proteins strongly enhance expression of a retrovirus harboured by a leptomeningeal cell line from a patient with multiple sclerosis," <u>Journal of General Virology</u> , Vol. 74, pp. 65-72, 1993.
59	Soldan, Samantha S. "Association of human herpes virus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA," Nature Medicine, Vol. 3, No. 12, pp. 1394-1397, 1997.
60	Haahr, S. "Is Multiple Sclerosis Caused by a Dual Infection with Retrovirus and Epstein-Barr Virus?," Neuroepidemiology, Vol. 11, pp. 229-303, 1992.
61	Bergstrom, Tomas et al. "Isolation of Herpes Simplex Virus Type 1 During First Attack of Multiple Sclerosis," <u>Ann. Neurol.</u> , Vol. 26, pp. 283-285, 1989.
62	Marx, Christine E. et al. "Cytokine Effects on Cortical Neuron MAP-2 Immunoreactivity: Implications for Schizophrenia," Biol. Psychiatry. Vol. 50, pp. 743-749, 2001.
63	Maes, Michael et al. "Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics," European Neuropsychopharmacology, Vol. 10, pp. 119-124, 2000.
64	Minagar, Alireza et al "The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer's disease, and multiple sclerosis," <u>Journal of the Neurological Sciences</u> , Vol. 202, pp. 13-23, 2002.
65	Jeohn, Gwang-Ho et al. "Go6976 Protects Mesencephalic Neurons from Lipopolysaccharide-Elicited Death by Inhibiting p38 MAP Kinase Phosphorylation," <u>Annals New York Academy of Sciences</u> , pp. 347-359.
66	Gaser, Christian et al. "Ventricular Enlargement in Schizophrenia Related to Volume Reduction of the Thalmus, Striatum, and Superior Temportal Cortex," <u>American Journal of Psychiatry</u> , Vol. 161, pp. 154-156, 2004.

68 Kurisson, H. et al. "HERP-W-related RNA detected in plasma from individuals with recent-enset schizophrenia or schizosffective disorder," Molecular Exchizor, Vol. 5, pp. 12-13, 2004. 69 Qia, Zibhiaa et al. "Intertexish-6, β-amyloid peptide and NMDA interactions in rat cortical neurous," Journal of Neurology, Vol. 139, pp. 51-57, 2003. 70 Jenner, Peter. "Oxidative Stress in Partinson's Disease," Annals of Neurology, Vol 53, Supp. 3, pp. 526-538, 2003. 71 Possible, David L. "Human viral supersatigens: to be or not to be transactivated?", Trends in Immunology, Vol. 23, No. 5, pp. 239, May 2002. 72 Parasstelli, Michael R. "Innovations in Drug Delivery to the Central Nervous System," Drugs of Today, Vol. 35, No. 6, pp. 435-448, 1999. 73 Merio, A. et al. "Comparing monoclosal antibodies and small peptidic hormones for local targeting of malignant gliomas," Acta. Neuroschiki, Vol. 88, Supp., pp. 18-91, 2003. 74 Antony, Joseph M. et al. "Human endogenous retrovirus glycoprotein-mediated induction of redox tractants causes digoedendropts death and demylenization," Autom. Relaxacience 2004. 75 Ng. Phillip C. et al. "Treparation and characterization of the Fab and F(ab'); fragments of aromatase activity-suppressing monoclonal antibody," Steroids, Vol. 62, pp. 76-781, 1997. 76 Perron, H. et al. "the Vitro transmission and antigenicity of a retrovirus isolated from a multiple sclerosis patient," Res. Vitrol. Vol. 143, pp. 337-350, 1995. 77 Serra, C. et al. "Multiple eclerosis and multiple sclerosis-associated retrovirus in Sardinia," Neurol. Sci., Vol. 22, pp. 171-173, 2001. 78 Serra, C. et al. "Multiple eclerosis and multiple sclerosis-associated retrovirus in Sardinia," Neurol. Sci., Vol. 22, pp. 171-173, 2001. 78 Serra, C. et al. "Multiple eclerosis and multiple sclerosis-associated retrovirus in Sardinia," Neurol. Sci., Vol. 22, pp. 171-173, 2001. 79 Serra, C. et al. "Multiple eclerosis and multiple sclerosis-associated retrovirus in Sardinia," Neurol. Sci., Vol. 22, pp. 171-173, 2001. 80 Rolland, Alexan		67	Kurtzke, John F. "Disability Rating Scales in Multiple Sclerosis," <u>Annals New York Academy of Sciences.</u> Vol. 36, pp. 347-360, 1984.
Percon, I. et al. "Future and and antipipe sciences are archives processing management and antipipe sciences associated error/us is addition." Percon, I. et al. "Autory, Sopp. No. et al. "Comparing on and antipipe sciences associated error/us is addition." Percon, I. et al. "Autory, Joseph Mr. et al. "Human endogenous retrovirus glycoprotein-mediated induction of redoc reactants causes of oligodesdrocyte death and demyclination." Nature Neuroscience, Vol. 7, No. 10, pp. 1088-1095, October 200, 1088-1095, Cercheer 200, 1088-1095, Cer		68	
Woodland, David L. "Human viral superantigens: to be or not to be transactivated?", Trends in Immunology, Vol. 23, No. 5, p. 239, May 2002. Pransatelli, Michael R. "Innovations in Drug Delivery to the Central Nervous System," Drugs of Today, Vol. 23, No. 6, pp. 435-448, 1999. Merlo, A. et al. "Comparing monoclonal antibodies and small peptidic hormones for local targeting of malignant gliomas," Acta. Naturely, Joseph M. et al. "Human endogenous retrovirus glycoprotein-mediated induction of redox reactant causes oligodendrocyte death and demyelination," Nature Neuroscience, Vol. 7, No. 10, pp. 1088-1095, Coeboer 2004. Ng. Phillip C. et al. "Preparation and characterization of the Fab and F(ab'); fragments of aromatase activity-suppressing monoclonal antibody," Sizeridis, Vol. 62, pp. 776-781, 1997. Perron, H. et al. "In Virro transmission and antigenicity of a retrovirus isolated from a multiple sclerosis patient," Res. Virol. 143, pp. 337-330, 1992. Serra, C. et al. "Multiple sclerosis and multiple sclerosis-associated retrovirus in Sardinia," Neurol. Sci., Vol. 22, pp. 171-173, 2001. Zavada, Mariota et al. "MSRV POL Sequence Copy Number as a Potential Marker of Multiple Sclerosis," Polish Journal of Patramacology, Vol. 55, pp. 869-875, 2003. Rolland, Alexandre. "Correlation between disease severity and in vitro cytokine production mediated by MSRV (Multiple Sclerosis," Viniology, Vol. 160, pp. 195-203, 2005. Komurian-Pradel, P. et al. "Molecular Coloning and Characterization of MSRV-Related Sequences Associated with Retrovirus-like particles," Viniology, Vol. 260, pp. 19, 1999. Perron, H. et al. "Human endogenous retrovirus (HERV)-W ENV and GAG proteins: Physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions," Journal of Neuroimmunology, Vol. 11, pp. 22-33, 2005. Blazar, Bruce R. et al. "Anti-CD3/Reby; Pragments Inhibit T Cell Expansion in Vivo During Graft-Versus-Host Disease or the Primary Immune Response to Nominal Antigen-Binding of 12, 199. pp. 82		69	
Pranostelli, Michael R. "Innovations in Drug Delivery to the Central Nervous System," <u>Drugs of Today.</u> Vol. 35, No. 6, pp. 435-448, 1999. Merio, A. et al. "Comparing monoclonal antibodies and small peptidic hormones for local targeting of malignant gliomas," <u>Acta Neuroscience</u> , Actael. (No. 88, Supp., pp. 83-91, 2003. Anticoy, Joseph M. et al. "Human endogenous retrovirus glycoprotein-mediated induction of redox rescinants causes oligodendrocyte death and demyelination," <u>Nature Neuroscience</u> , Vol. 7, No. 10, pp. 1088-1095, October 2004. Ng. Phillip C. et al. "Preparation and characterization of the Pab and P(ab'); fragments of aromatase activity-suppressing monoclonal antibody," <u>Steroids</u> , Vol. 62, pp. 776-781, 1997. Peron. H. et al. "Multiple sclerosis and multiple sclerosis-associated retrovirus in Sardinia," <u>Neurol. Scl.</u> , Vol. 22, pp. 171-173, 2001. Serra, C. et al. "Multiple sclerosis and multiple sclerosis-associated retrovirus in Sardinia," <u>Neurol. Scl.</u> , Vol. 22, pp. 171-173, 2001. Zawada, Mariota et al. "MSRV POL Sequence Copy Number as a Potential Marker of Multiple Sclerosis," <u>Polish Journal of Pharmacology</u> , Vol. 55, pp. 80-875, 2005. Rolland, Alexandre. "Correlation between disease severity and in vitro cytokine production mediated by MSRV (Multiple Sclerosis associated Retro Viral element) envelope protein in patients with multiple sclerosis, " <u>Fournal of Neuroimmunology</u> , Vol. 160, pp. 195-203, 2005. Komurian-Pradel, P. et al. "Molecular Cloning and Characterization of MSRV-Related Sequences Associated with Retrovirus-like particles," <u>Vilology</u> , Vol. 20, pp. 199. Perron, H. et al. "Human endogenous retrovirus (HERV)-W ENV and GAG proteins: Physiological expression in human brain and pathophysiclogical modalisation in multiple sclerosis lesions," <u>Summal of NeuroVirology</u> , Vol. 11, pp. 23-33, 2005, Bird, Robert E. et al. "Single-Chain Antigen-Binding Proteins," <u>Science Reports</u> , Vol. 242, pp. 423-426, Coetober 21, 1988. Arakawa, Pumiko et al. "Ciontinuous cultures of fused cell		70	Jenner, Peter. "Oxidative Stress in Parkinson's Disease," Annals of Neurology, Vol 53, Supp. 3, pp. \$26-\$38, 2003.
Merlo, A. et al. "Comparing monoclonal autibodies and small peptidic hormones for local targeting of malignant gliomas," Acta. Neutrockiii. Vol. 88, Supp., pp. 83-91, 2003. Antony, Joseph M. et al. "Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyclination," Nature Neutroscience, Vol. 7, No. 10, pp. 1088-1095, October 2004. 75		71	
Neurochir. Vol. 88, Supp., pp. 83-91, 2003. 74 Antony, Joseph M. et al. "Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oilgodendrocyte death and demyclinistion." Nature Neuroscience. Vol. 7, No. 10, pp. 1088-1095, October 2004. 75 Ne, Phillip C. et al. "Preparation and characterization of the Fab and F(ab'); fragments of aromatase activity-suppressing monoclonal antibody." Steroids. Vol. 62, pp. 776-781, 1997. 76 Perron, H. et al. "In Vitro transmission and antigenicity of a retrovirus isolated from a multiple sclerosis patient," Res. Virol. Vol. 143, pp. 337-350, 1992. 77 Serra, C. et al. "Multiple sclerosis and multiple sclerosis-associated retrovirus in Sardinia." Neurol. Sci., Vol. 22, pp. 171-173, 2001. 78 Serra, C. et al. "Multiple sclerosis and multiple sclerosis-associated retrovirus in Sardinia." Neurol. Sci., Vol. 22, pp. 171-173, 2001. 78 Rolland, Alexandre. "Correlation between disease severity and in vitro cytokine production mediated by MSRV (Multiple Sclerosis associated Retro Viral element) envelope protein in patients with multiple sclerosis," Journal of Neuroimmunology. Vol. 160, pp. 195-203, 2005. 80 Rolland, Alexandre. "Correlation between disease severity and in vitro cytokine production mediated by MSRV (Multiple Sclerosis associated Retro Viral element) envelope protein in patients with multiple sclerosis, "Journal of Neuroimmunology. Vol. 160, pp. 19-2, 1999. 81 Perron, H. et al. "Human endogenous retrovirus (HERV)-W ENV and GAG proteins: Physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions," Journal of Neuroimpoly, Vol. 11, pp. 23-33, 2005, and pathophysiological modulation in multiple sclerosis lesions," Journal of Neuroimpoly, Vol. 11, pp. 23-33, 2005, and pathophysiological modulation in multiple sclerosis lesions, "Journal of Neuroimpoly, Vol. 11, pp. 23-33, 2005, and pp. 19-19-199. 81 Blazar, Bruce R. et al. "Auti-CDa'P, Rab'y-Pagments Inhibit T Cell Expansion in Vivo During Carri-Ve		72	
oligodeadrocyte death and demyelination," Nature Neuroscience, Vol. 7, No. 10, pp. 1088-1095, October 2004. 75 Ng. Phillip C. et al. "Preparation and characterization of the Fab and F(ab'); fragments of aromatase activity-suppressing monoclonal antibody," Siercids, Vol. 62, pp. 776-781, 1997. 76 Perron, H. et al. "in Vitro transmission and antigenicity of a retrovirus isolated from a multiple sclerosis patient," Res. Vitrol. Vol. 143, pp. 337-350, 1992. 77 Serra, C. et al. "Multiple sclerosis and multiple sclerosis-associated retrovirus in Sardinia," Neurol. Sci., Vol. 22, pp. 171-173, 2001. 78 Zawada, Mariola et al. "MSRV POL Sequence Copy Number as a Potential Marker of Multiple Sclerosis," Polish Journal of Pharmacology, Vol. 55, pp. 869-875, 2003. 78 Rolland, Alexandre. "Correlation between disease severity and in vitro cytokine production mediated by MSRV (Multiple Sclerosis, associated Retro Viral elementy envelope protein in patients with multiple sclerosis," Journal of Neuroimmunology. Vol. 160, pp. 195-203, 2005. 80 Rolland, Alexandre. "Correlation between disease severity and in vitro cytokine production mediated by MSRV (Multiple Sclerosis, Polish Journal of Neuroimmunology. Vol. 160, pp. 195-203, 2005. 80 Komurian-Pradel, P. et al. "Molecular Cloning and Characterization of MSRV-Related Sequences Associated with Retrovirus-like particles," Virology. Vol. 260, pp. 1-9, 1999. 81 Perron, H. et al. "Human endogenous retrovirus (HERV)-W ENV and GAG proteins: Physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions," Journal of NeuroVirology, Vol. 179, pp. 25-32, 2005. 82 Bird, Robert E. et al. "Single-Chain Antigen-Binding Proteins," Science Reports. Vol. 242, pp. 423-426, October 21, 1988. 83 Bird, Robert E. et al. "Single-Chain Antigen-Binding Proteins," Science Reports. Vol. 242, pp. 423-426, October 21, 1988. 84 Arakawa, Furniko et al. "Cloning and Sequencing the V ₁ and V ₂ Genes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mou		73	
monoclonal antibody, "Steroids, Vol. 62, pp. 776-781, 1997. Perron, H. et al. "In Vitro transmission and antigenicity of a retrovirus isolated from a multiple sclerosis patient," Res. Virol. Vol. 143, pp. 337-350, 1992. 25 Serra, C. et al. "Multiple sclerosis and multiple sclerosis-associated retrovirus in Sardinia," Neurol. Sci., Vol. 22, pp. 171-173, 2001. 78 Zawada, Mariola et al. "MSRV POL Sequence Copy Number as a Potential Marker of Multiple Sclerosis," Polish Journal of Pharmacology, Vol. 55, pp. 869-875, 2003. Rolland, Alexandre. "Correlation between disease severity and in vitro cytokine production mediated by MSRV (Multiple Sclerosis associated Retro Viral element) envelope protein in patients with multiple sclerosis," Journal of Neuroimmunology, Vol. 160, pp. 195-203, 2005. 80 Komurian-Pradel, F. et al. "Molecular Cloning and Characterization of MSRV-Related Sequences Associated with Retrovirus-like particles," Virology, Vol. 260, pp. 1-9, 1999. 81 Perron, H. et al. "Human endogenous retrovirus (HERV)-W ENV and GAG proteins: Physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions," Journal of NeuroVirology, Vol. 11, pp. 23-33, 2005. 84 Blazar, Bruce R. et al. "Anti-CD3," (ab') ₂ Ragments Inhibit T Cell Expansion in Vivo During Graft-Versus-Host Disease or the Primary Immune Response to Nominal Antigen-Binding Proteins," Science Reports, Vol. 124, pp. 423-426, October 21, 1988. 85 Bird, Robert E. et al. "Single-Chain Antigen-Binding Proteins," Science Reports, Vol. 242, pp. 423-426, October 21, 1988. 86 Arakawa, Furnito et al. "Cloning and Sequencing the V ₁ and V ₂ Genes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody," Journal Biochem. Vol. 120, pp. 657-662, 1996. 87 Chaudhary, Vijay K. et al. "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin." Nature, Vol. 339, pp. 394-397, June 1, 1989. 88 Jiang, Qingqi et al. "Cutting Edge: Lipopolysaccharide Ind		74	
Vol. 143, pp. 337-350, 1992. Serra, C. et al. "Multiple sclerosis and multiple sclerosis-associated retrovirus in Sardinia," Neurol. Sci., Vol. 22, pp. 171-173, 2001. Zawada, Mariola et al. "MSRV POL Sequence Copy Number as a Potential Marker of Multiple Sclerosis," Polish Journal of Pharmacology. Vol. 55, pp. 869-875, 2003. Rolland, Alexandre. "Correlation between disease severity and in vitro cytokine production mediated by MSRV (Multiple Sclerosis associated Retro Viral element) envelope protein in patients with multiple sclerosis," Journal of Neuroimmunology. Vol. 160, pp. 195-203, 2005. Komurian-Pradel, F. et al. "Molecular Cloning and Characterization of MSRV-Related Sequences Associated with Retrovirus-like particles," Virology. Vol. 260, pp. 1-9, 1999. 81 Perron, H. et al. "Human endogenous retrovirus (HERV)-W ENV and GAG proteins: Physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions," Journal of NeuroVirology, Vol. 11, pp. 23-33, 2005. 84 Blazar, Bruce R. et al. "Anti-CD3," (ab'): Pragments Inhibit T Cell Expansion in Vivo During Graft-Versus-Host Disease or the Primary Immune Response to Nominal Antigen." Journal of Immunology. Vol. 159, pp. 5821-5833, 1997. 83 Bird, Robert E. et al. "Single-Chain Antigen-Binding Proteins," Science Reports. Vol. 242, pp. 423-426, October 21, 1988. 44 Arakawa, Furniko et al. "Cloning and Sequencing the V ₁ and V ₂ Genes of an Anti-CD3 Monoclonal Antibody, and Construction of Amous-Pfluman Chimeric Antibody," Journal Biochem. Vol. 120, pp. 657-662, 1996. Chaudhary, Vijay K. et al. "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin," Nature, Vol. 399, pp. 394-397, June 1, 1989. Mishra, Nirmal K. et al. "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, Vol. 256, pp. 495-500, August 7, 1975. 87 Galfre, G. et al. "Antibodies to major histocompatability antigens produced by hybrid cell lines," Nature, Vol. 256, pp. 55		75	
2001. 2awada, Mariola et al. "MSRV POL Sequence Copy Number as a Potential Marker of Multiple Sclerosis," Polish Journal of Parmacology. Vol. 55, pp. 869-875, 2003. Rolland, Alexandre. "Correlation between disease severity and in vitro cytokine production mediated by MSRV (Multiple Sclerosis associated Retro Viral element) envelope protein in patients with multiple sclerosis," Journal of Neuroimmunology. Vol. 160, pp. 195-203, 2005. Rolland, Alexandre. "Correlation between disease severity and in vitro cytokine production mediated by MSRV (Multiple Sclerosis associated Retro Viral element) envelope protein in patients with multiple sclerosis," Journal of Neuroimmunology. Vol. 160, pp. 195-203, 2005. Rolland, Alexandre. "Correlation between disease severity and in vitro cytokine production mediated by MSRV (Multiple Sclerosis) esions associated with Retrovirus-like particles," Virology, Vol. 260, pp. 1-9, 1999. Rolland, Alexandre. "Virology, Vol. 260, pp. 1-9, 1999. Perron, H. et al. "Human endogenous retrovirus (HERV)-W ENV and GAG proteins: Physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions," Journal of Neuroy Vol. 11, pp. 23-33, 2005, Blazar, Bruce R. et al. "Anti-CD3,F (ab'); Pragments Inhibit T Cell Expansion in Vivo During Graft-Versus-Host Disease or the Primary Immune Response to Nominal Antigen." Journal of Immunology. Vol. 159, pp. 5821-5833, 1997. Bird, Robert E. et al. "Single-Chain Antigen-Binding Proteins," Science Reports, Vol. 259, pp. 5821-5833, 1997. Arakawa, Purniko et al. "Cloning and Sequencing the V ₁ and V ₈ Genes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody," Journal Biochem. Vol. 120, pp. 657-662, 1996. Chaudhary, Vijay K. et al. "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin," Nature, Vol. 239, pp. 394-397, June 1, 1989. Bis Chaudhary, Vijay K. et al. "A recombinant immunotoxin consisting of two antibody variable domains fused	111111111	76	
Pharmacology. Vol. 55, pp. 869-875, 2003. Rolland, Alexandre. "Correlation between disease severity and in vitro cytokine production mediated by MSRV (Multiple Sclerosis associated Retro Viral element) envelope protein in patients with multiple sclerosis," **Iournal of Neuroimmunology.**Vol. 160, pp. 195-203, 2005. 80		77	
Sclerosis associated Retro Viral element) envelope protein in patients with multiple sclerosis," Journal of Neuroimmunology. Vol. 160, pp. 195-203, 2005. Komurian-Pradel, P. et al. "Molecular Cloning and Characterization of MSRV-Related Sequences Associated with Retrovirus-like particles," Virology. Vol. 260, pp. 1-9, 1999. 81 Perron, H. et al. "Human endogenous retrovirus (HERV)-W ENV and GAG proteins: Physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions," Journal of NeuroVirology, Vol. 11, pp. 23-33, 2005, 84 Blazar, Bruce R. et al. "Anti-CD3,P (ab'): Pragments Inhibit T Cell Expansion in Vivo During Graft-Versus-Host Disease or the Primary Immune Response to Nominal Antigen." Journal of Immunology, Vol. 159, pp. 5821-5833, 1997. 83 Bird, Robert E. et al. "Single-Chain Antigen-Binding Proteins," Science Reports, Vol. 242, pp. 423-426, October 21, 1988. 84 Arakawa, Pumiko et al. "Cloning and Sequencing the V _H and V _K Genes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody," Journal Biochem. Vol. 120, pp. 657-662, 1996. 85 Chaudhary, Vijay K. et al. "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin," Nature, Vol. 339, pp. 394-397, June 1, 1989. 86 Mishra, Nirmal K. et al. "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, Vol. 256, pp. 495-550, August 7, 1975. 87 Galfre, G. et al. "Antibodies to major histocompatability antigens produced by hybrid cell lines," Nature, Vol. 256, pp. 550-552, August 7, 1975. 88 Jiang, Qingqi et al. "Cutting Edge: Lipopolysaccharide Induces Physical Proximity Between CD14 and Toll-Like Receptor 4 (TLR4) Prior to Nuclear Translocation of AP- _K B. "Journal of Immunology, Vol. 165, pp. 3541-3544, 2000. 89 Lehnardt, Seija. "The Toll-Like Receptor TLR4 is Necessary for Lipopolysaccharide-Induced Oligodendrocyte Injury in the CNS," Journal of NeuroScience, Vol. 22, No. 7, pp. 2478-2486, April 1, 2		78	Zawada, Mariola et al. "MSRV POL Sequence Copy Number as a Potential Marker of Multiple Sclerosis," Polish Journal of Pharmacology, Vol. 55, pp. 869-875, 2003.
particles," <u>Virology.</u> Vol. 260, pp. 1-9, 1999. 81 Perron, H. et al. "Human endogenous retrovirus (HERV)-W ENV and GAG proteins: Physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions," <u>Journal of NeuroVirology.</u> Vol. 11, pp. 23-33, 2005. 84 Blazar, Bruce R. et al. "Anti-CD3 ₄ " (ab') ₂ Pragments Inhibit T Cell Expansion in Vivo During Graft-Versus-Host Disease or the Primary Immune Response to Nominal Antigen." <u>Journal of Immunology.</u> Vol. 159, pp. 5821-5833, 1997. 83 Bird, Robert E. et al. "Single-Chain Antigen-Binding Proteins," <u>Science Reports.</u> Vol. 242, pp. 423-426, October 21, 1988. 84 Arakawa, Furniko et al. "Cloning and Sequencing the V _H and V _K Genes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody." <u>Journal Biochem.</u> Vol. 120, pp. 657-662, 1996. 85 Chaudhary, Vijay K. et al. "A recombinant immunotoxin consisting of two antibody variable domains fused to <i>Pseudomonas</i> exotoxin," <u>Nature.</u> Vol. 339, pp. 394-397, June 1, 1989. 86 Mishra, Nirmal K. et al. "Continuous cultures of fused cells secreting antibody of predefined specificity," <u>Nature.</u> Vol. 256, pp. 495-550, August 7, 1975. 87 Galfre, G. et al. "Antibodies to major histocompatability antigens produced by hybrid cell lines," <u>Nature.</u> Vol. 256, pp. 550-552, August 7, 1975. 88 Jiang, Qingqi et al. "Cutting Edge: Lipopolysaccharide Induces Physical Proximity Between CD14 and Toll-Like Receptor 4 (TLR4) Prior to Nuclear Translocation of AP- _K B," <u>Journal of Immunology.</u> Vol. 165, pp. 3541-3544, 2000. 89 Lehnardt, Seija. "The Toll-Like Receptor TLR4 is Necessary for Lipopolysaccharide-Induced Oligodendrocyte Injury in the CNS," <u>Journal of NeuroScience.</u> Vol. 22, No. 7, pp. 2478-2486, April 1, 2002. 90 Serra, Caterina et al. "In Vitro modulation of the multiple sclerosis (MS)-associated retrovirus by cytokines: Implications for MS pathogenesis," <u>Journal of NeuroVirology.</u> Vol. 9, pp. 637-643, 2003. DATE CONSIDERED		79	Sclerosis associated Retro Viral element) envelope protein in patients with multiple sclerosis," Journal of Neuroimmunology,
and pathophysiological modulation in multiple sclerosis lesions," <u>Journal of NeuroVirology</u> , Vol. 11, pp. 23-33, 2005, Blazar, Bruce R. et al. "Anti-CD3 _x P (ab') ₂ Fragments Inhibit T Cell Expansion in Vivo During Graft-Versus-Host Disease or the Primary Immune Response to Nominal Antigen," <u>Journal of Immunology</u> , Vol. 159, pp. 5821-5833, 1997. Bird, Robert E. et al. "Single-Chain Antigen-Binding Proteins," <u>Science Reports</u> , Vol. 242, pp. 423-426, October 21, 1988. Arakawa, Fumiko et al. "Cloning and Sequencing the V _H and V _K Genes ef an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody," <u>Journal Biochem</u> , Vol. 120, pp. 657-662, 1996. Chaudhary, Vijay K. et al. "A recombinant immunotoxin consisting of two antibody variable domains fused to <i>Pseudomonas</i> exotoxin," Nature, Vol. 339, pp. 394-397, June 1, 1989. Mishra, Nirmal K. et al. "Continuous cultures of fused cells secreting antibody of predefined specificity," <u>Nature</u> , Vol. 256, pp. 495-550, August 7, 1975. Galfre, G. et al. "Antibodies to major histocompatability antigens produced by hybrid cell lines," <u>Nature</u> , Vol. 256, pp. 550-552, August 7, 1975. Biang, Qingqi et al. "Cutting Edge: Lipopolysaccharide Induces Physical Proximity Between CD14 and Toll-Like Receptor 4 (TLR4) Prior to Nuclear Translocation of AF- _K B," <u>Journal of Immunology</u> , Vol. 165, pp. 3541-3544, 2000. Lehnardt, Seija. "The Toll-Like Receptor TLR4 is Necessary for Lipopolysaccharide-Induced Oligodendrocyte Injury in the CNS," <u>Journal of Neuroscience</u> , Vol. 22, No. 7, pp. 2478-2486, April 1, 2002. Serra, Caterina et al. "In Vitro modulation of the multiple sclerosis (MS)-associated retrovirus by cytokines: Implications for MS pathogenesis," <u>Journal of NeuroVirology</u> , Vol. 9, pp. 637-643, 2003. DATE CONSIDERED		80	
Primary Immune Response to Nominal Antigen." Journal of Immunology. Vol. 159, pp. 5821-5833, 1997. Bird, Robert E. et al. "Single-Chain Antigen-Binding Proteins," Science Reports, Vol. 242, pp. 423-426, October 21, 1988. Arakawa, Fumiko et al. "Cloning and Sequencing the V _H and V _K Genes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody," Journal Biochem, Vol. 120, pp. 657-662, 1996. Chaudhary, Vijay K. et al. "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin," Nature, Vol. 339, pp. 394-397, June 1, 1989. Mishra, Nirmal K. et al. "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, Vol. 256, pp. 495-550, August 7, 1975. Galfre, G. et al. "Antibodies to major histocompatability antigens produced by hybrid cell lines," Nature, Vol. 256, pp. 550-552, August 7, 1975. Jiang, Qingqi et al. "Cutting Edge: Lipopolysaccharide Induces Physical Proximity Between CD14 and Toll-Like Receptor 4 (TLR4) Prior to Nuclear Translocation of AF- _K B," Journal of Immunology. Vol. 165, pp. 3541-3544, 2000. Lehnardt, Seija. "The Toll-Like Receptor TLR4 is Necessary for Lipopolysaccharide-Induced Oligodendrocyte Injury in the CNS," Journal of Neuroscience. Vol. 22, No. 7, pp. 2478-2486, April 1, 2002. Serra, Caterina et al. "In Vitro modulation of the multiple sclerosis (MS)-associated retrovirus by cytokines: Implications for MS pathogenesis," Journal of NeuroVirology, Vol. 9, pp. 637-643, 2003. DATE CONSIDERED Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance		81	Perron, H. et al. "Human endogenous retrovirus (HERV)-W ENV and GAG proteins: Physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions," <u>Journal of NeuroVirology</u> , Vol. 11, pp. 23-33, 2005.
Arakawa, Fumiko et al. "Cloning and Sequencing the V _H and V _K Genes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody," Journal Biochem. Vol. 120, pp. 657-662, 1996. Chaudhary, Vijay K. et al. "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin," Nature, Vol. 339, pp. 394-397, June 1, 1989. Mishra, Nirmal K. et al. "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, Vol. 256, pp. 495-550, August 7, 1975. Galfre, G. et al. "Antibodies to major histocompatability antigens produced by hybrid cell lines," Nature, Vol. 256, pp. 550-552, August 7, 1975. Jiang, Qingqi et al. "Cutting Edge: Lipopolysaccharide Induces Physical Proximity Between CD14 and Toll-Like Receptor 4 (TLR4) Prior to Nuclear Translocation of AP- _K B," Journal of Immunology, Vol. 165, pp. 3541-3544, 2000. Lehnardt, Seija. "The Toll-Like Receptor TLR4 is Necessary for Lipopolysaccharide-Induced Oligodendrocyte Injury in the CNS," Journal of Neuroscience, Vol. 22, No. 7, pp. 2478-2486, April 1, 2002. Serra, Caterina et al. "In Vitro modulation of the multiple sclerosis (MS)-associated retrovirus by cytokines: Implications for MS pathogenesis," Journal of NeuroVirology, Vol. 9, pp. 637-643, 2003. DATE CONSIDERED Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance		84	
of a Mouse/Human Chimeric Antibody," Journal Biochem. Vol. 120, pp. 657-662, 1996. 85 Chaudhary, Vijay K. et al. "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin," Nature. Vol. 339, pp. 394-397, June 1, 1989. 86 Mishra, Nirmal K. et al. "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, Vol. 256, pp. 495-550, August 7, 1975. 87 Galfre, G. et al. "Antibodies to major histocompatability antigens produced by hybrid cell lines," Nature, Vol. 256, pp. 550-552, August 7, 1975. 88 Jiang, Qingqi et al. "Cutting Edge: Lipopolysaccharide Induces Physical Proximity Between CD14 and Toll-Like Receptor 4 (TLR4) Prior to Nuclear Translocation of AF _R B, "Journal of Immunology, Vol. 165, pp. 3541-3544, 2000. 89 Lehnardt, Seija. "The Toll-Like Receptor TLR4 is Necessary for Lipopolysaccharide-Induced Oligodendrocyte Injury in the CNS," Journal of Neuroscience, Vol. 22, No. 7, pp. 2478-2486, April 1, 2002. 90 Serra, Caterina et al. "In Vitro modulation of the multiple sclerosis (MS)-associated retrovirus by cytokines: Implications for MS pathogenesis," Journal of NeuroVirology, Vol. 9, pp. 637-643, 2003. EXAMINER DATE CONSIDERED Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance		83	Bird, Robert E. et al. "Single-Chain Antigen-Binding Proteins," Science Reports, Vol. 242, pp. 423-426, October 21, 1988.
exotoxin," Nature. Vol. 339, pp. 394-397, June 1, 1989. Mishra, Nirmal K. et al. "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, Vol. 256, pp. 495-550, August 7, 1975. Galfre, G. et al. "Antibodies to major histocompatability antigens produced by hybrid cell lines," Nature, Vol. 256, pp. 550-552, August 7, 1975. Biang, Qingqi et al. "Cutting Edge: Lipopolysaccharide Induces Physical Proximity Between CD14 and Toll-Like Receptor 4 (TLR4) Prior to Nuclear Translocation of AF-kB," Journal of Immunology. Vol. 165, pp. 3541-3544, 2000. Lehnardt, Seija. "The Toll-Like Receptor TLR4 is Necessary for Lipopolysaccharide-Induced Oligodendrocyte Injury in the CNS," Journal of Neuroscience, Vol. 22, No. 7, pp. 2478-2486, April 1, 2002. Serra, Caterina et al. "In Vitro modulation of the multiple sclerosis (MS)-associated retrovirus by cytokines: Implications for MS pathogenesis," Journal of NeuroVirology, Vol. 9, pp. 637-643, 2003. EXAMINER DATE CONSIDERED		84	Arakawa, Fumiko et al. "Cloning and Sequencing the V_H and V_K Genes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody," <u>Journal Biochem</u> , Vol. 120, pp. 657-662, 1996.
495-550, August 7, 1975. 87 Galfre, G. et al. "Antibodies to major histocompatability antigens produced by hybrid cell lines," Nature, Vol. 256, pp. 550-552, August 7, 1975. 88 Jiang, Qingqi et al. "Cutting Edge: Lipopolysaccharide Induces Physical Proximity Between CD14 and Toll-Like Receptor 4 (TLR4) Prior to Nuclear Translocation of AF- _K B," Journal of Immunology, Vol. 165, pp. 3541-3544, 2000. 89 Lehnardt, Seija. "The Toll-Like Receptor TLR4 is Necessary for Lipopolysaccharide-Induced Oligodendrocyte Injury in the CNS," Journal of Neuroscience. Vol. 22, No. 7, pp. 2478-2486, April 1, 2002. 90 Serra, Caterina et al. "In Vitro modulation of the multiple selectoris (MS)-associated retrovirus by cytokines: Implications for MS pathogenesis," Journal of NeuroVirology, Vol. 9, pp. 637-643, 2003. EXAMINER DATE CONSIDERED Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance		85	Chaudhary, Vijay K. et al. "A recombinant immunotoxin consisting of two antibody variable domains fused to <i>Pseudomonas</i> exotoxin," Nature, Vol. 339, pp. 394-397, June 1, 1989.
August 7, 1975. Salang, Qingqi et al. "Cutting Edge: Lipopolysaccharide Induces Physical Proximity Between CD14 and Toll-Like Receptor 4 (TLR4) Prior to Nuclear Translocation of AP _R B, "Journal of Immunology, Vol. 165, pp. 3541-3544, 2000. Salang		86	Mishra, Nirmal K. et al. "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, Vol. 256, pp. 495-550, August 7, 1975.
(TLR4) Prior to Nuclear Translocation of AF- _K B, "Journal of Immunology. Vol. 165, pp. 3541-3544, 2000. 89 Lehnardt, Seija. "The Toll-Like Receptor TLR4 is Necessary for Lipopolysaccharide-Induced Oligodendrocyte Injury in the CNS," Journal of Neuroscience, Vol. 22, No. 7, pp. 2478-2486, April 1, 2002. 90 Serra, Caterina et al. "In Vitro modulation of the multiple sclerosis (MS)-associated retrovirus by cytokines: Implications for MS pathogenesis," Journal of NeuroVirology, Vol. 9, pp. 637-643, 2003. EXAMINER Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance		87	
CNS," <u>Journal of Neuroscience</u> , Vol. 22, No. 7, pp. 2478-2486, April 1, 2002. Serra, Caterina et al. "In Vitro modulation of the multiple sclerosis (MS)-associated retrovirus by cytokines: Implications for MS pathogenesis," <u>Journal of NeuroVirology</u> , Vol. 9, pp. 637-643, 2003. EXAMINER Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance		88	
pathogenesis," <u>Journal of NeuroVirology.</u> Vol. 9, pp. 637-643, 2003. EXAMINER DATE CONSIDERED Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance		89	Lehnardt, Seija. "The Toll-Like Receptor TLR4 is Necessary for Lipopolysaccharide-Induced Oligodendrocyte Injury in the CNS," <u>Journal of Neuroscience</u> . Vol. 22, No. 7, pp. 2478-2486, April 1, 2002.
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance		90	Serra, Caterina et al. "In Vitro modulation of the multiple sclerosis (MS)-associated retrovirus by cytokines: Implications for MS pathogenesis," <u>Journal of NeuroVirology</u> , Vol. 9, pp. 637-643, 2003.
	EXAMINER		DATE CONSIDERED
	Examiner:	Initial if c	itation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance used details. Include copy of this form with next communication to applicant.